Nature Reviews Drug Discovery 7, 641 (2008). Authors: Gil Y. Melmed, Stephan R. Targan, Uma Yasothan, Delphine Hanicq & Peter Kirkpatrick In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have not responded to conventional therapies. Ver [...]
Nature Clinical Practice Rheumatology 4, 565 (2008). Ver artigo completo
Lisa GM van Baarsen, Carina L Bos, Tineke CTM van der Pouw Kraan and Cornelis L Verweij Arthritis Research & Therapy - Latest articles Rheumatic diseases represent a diverse group of disorders. Most of these diseases are heterogeneous in nature, and show varying responsiveness to treatment. Since our understanding of the molecular complexity is incomplete and [...]
Arthritis / Rheumatology News From Medical News Today You come into a doctor's office with severe knee pain. The physician orders an MRI, which reveals substantial loss of cartilage-osteoarthritis, that is-in your knee joint. At this point, not much can be done beyond gulping down palliatives and trying to keep your weight off the joint. But [...]
Arthritis / Rheumatology News From Medical News Today Scientists at UCSF have discovered an abnormality in a patient's immune system that may lead to safer therapies for autoimmune diseases such as rheumatoid arthritis and colitis, as well as potential new ways to treat transplant rejection. The research identified antibodies from a woman's immune system that prevent [...]
Hachulla, E., Carpentier, P., Gressin, V., Diot, E., Allanore, Y., Sibilia, J., Launay, D., Mouthon, L., Jego, P., Cabane, J., de Groote, P., Chabrol, A., Lazareth, I., Guillevin, L., Clerson, P., Humbert, M., the ItinerAIR-Sclerodermie Study Investigator Objectives. This longitudinal study investigated survival, risk factors and causes of death in the multicentre ItinérAIR-Sclérodermie cohort of patients with [...]
Arthritis / Rheumatology News From Medical News Today Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed rheumatologists say that a therapy's effect on reducing the signs and symptoms of rheumatoid arthritis at one year is the attribute that most influences their prescribing decisions in treating [...]
John Kirwan Abstract Although low-dose glucocorticoids, in conjunction with DMARDs, are known to halt or severely retard the erosive destruction of joints in patients with early rheumatoid arthritis (RA), the potential adverse effects of low-dose glucocorticoids and the benefit:risk ratio of treatment are a concern for many clinicians. Malysheva and colleagues undertook a retrospective, open-label review [...]
Abstract Original article Genovese MC et al. (2008) Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 58: 2652–2661 PubMed Ver artigo completo
Original article Giles JT et al. (2008) Association of body composition with disability in rheumatoid arthritis: impact of appendicular fat and lean tissue mass. Arthritis Rheum 15: 1407–1415 Article Increased body fat mass and decreased lean body mass are independently correlated with impaired physical function in patients with rheumatoid arthritis (RA); body fat mass and lean mass in the [...]